AGIO Stock Summary and Trading Ideas (Agios Pharmaceuticals | NASDAQ:AGIO)

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Agios Pharmaceuticals trades on the NASDAQ stock market under the symbol AGIO.

As of July 15, 2026, AGIO stock price declined to $39.87 with 606,507 million shares trading.

AGIO has a beta of 2.28, meaning it tends to be more sensitive to market movements. AGIO has a correlation of 0.12 to the broad based SPY ETF.

AGIO has a market cap of $2.37 billion. This is considered a Mid Cap stock.

Last quarter Agios Pharmaceuticals reported $21 million in Revenue and -$1.69 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.10.

In the last 3 years, AGIO traded as high as $62.58 and as low as $19.80.

The top ETF exchange traded funds that AGIO belongs to (by Net Assets): XBI, IWM, VTI, VB, VBK.

AGIO has underperformed the market in the last year with a return of +1.6%, while SPY returned +22.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in AGIO shares. However, AGIO has outperformed the market in the last 3 month and 2 week periods, returning +19.7% and +7.4%, while SPY returned +9.0% and +1.1%, respectively. This indicates AGIO has been having a stronger performance recently.

AGIO support price is $38.62 and resistance is $41.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGIO shares will trade within this expected range on the day.